Prostate cancer treatment and research at Dana-Farber
While prostate cancer survival rates have improved considerably over the past 20 years, it is still the second leading cause of cancer death in men.
Dana-Farber's team of prostate cancer experts has pioneered unique treatment approaches and new methods for assessing cancer control that have resulted in better cure rates with fewer side effects for men with this disease.
Related Stories
- Grant furthers efforts to develop more effective treatments for metastatic prostate cancer (October 18, 2007)
- Androgen deprivation therapy for prostate cancer may increase risk of death from cardiovascular disease in older men, study finds (February 27, 2007)
- Scientists identify a region of the human genome leading to an elevated prostate cancer risk in African American men (Aug. 23, 2006)
- Failure of PSA levels to fall in prostate cancer patients may lead to poor outcomes (Sept. 28, 2005)
- Study finds that black men are significantly less likely to undergo prostate cancer screening (Sept. 27, 2004)
- Short course of hormonal therapy improves survival in prostate cancer patients treated with radiation therapy (Aug. 17, 2004)
- Study suggests value of regular PSA tests for tracking prostate cancer (July 15, 2004)
- DFCI grant program aims to accelerate research for treatment of solid tumors, including lung, breast, prostate, and colorectal cancers (Feb. 11, 2004)
- Common screening test may be missing majority of prostate cancers (July 23, 2003)
- SPORE grant targets prostate cancer (Aug. 22, 2002)
